You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 130 No. 1, January 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Long-term Morbidity After Regional Isolated Perfusion With Melphalan for Melanoma of the Limbs

The Influence of Acute Regional Toxic Reactions

Bart C. Vrouenraets, MD; Joost M. Klaase, MD, PhD; Bin B. R. Kroon, MD, PhD; Bert N. van Geel, MD, PhD; Alexander M. M. Eggermont, MD, PhD; Hilary R. Franklin

Arch Surg. 1995;130(1):43-47.


Abstract

Objective
To determine the influence of acute regional toxic reactions on the incidence and characteristics of long-term morbidity after regional isolated perfusion with melphalan.

Design
Retrospective study.

Setting
The Amsterdam and Rotterdam perfusion centers, the Netherlands.

Patients
All patients with melanoma who were treated between 1978 and 1990 and had a minimum follow-up of 1 year after perfusion (n=367).

Intervention
Fifty-four patients (15%) had perfusion of the upper limb, 313 (85%) had perfusion of the lower limb, and 164 patients (45%) underwent regional lymph node dissection at the time of perfusion.

Main Outcome Measure
Incidence and characteristics of morbidity 1 year after perfusion and the influence of acute regional toxic reactions on long-term morbidity.

Results
One hundred sixty patients (44%) showed some degree of objective or subjective morbidity; most (104 [28%]) had lymphedema. Other long-term morbidity consisted of muscle atrophy or fibrosis (42 [11%]), limb malfunction (55 [15%]), neuropathy (13 [4%]), pain (28 [8%]), and recurrent infection (11 [3%]). Miscellaneous complications were seen in 14 patients (4%). Seventy-one patients (19%) had more than one complication. Acute regional toxic reactions had a statistically significant effect on the incidence of long-term morbidity (P<.01). Moderate to severe acute regional toxic reactions were strongly linked to the occurrence of muscle atrophy or fibrosis (P<.001) and limb malfunction (P<.001). Regional lymph node dissection was statistically significantly related to lymphedema (P=.05).

Conclusion
Improvement of the perfusion technique should be pursued in an effort to reduce acute regional toxic reactions, and thereby long-term morbidity, without compromising the therapeutic effect.

(Arch Surg. 1995;130:43-47)



Author Affiliations

From the Departments of Surgery, the Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Amsterdam (Drs Vrouenraets, Klaase, and Kroon and Ms Franklin), and the Dr Daniel den Hoed Cancer Center, Rotterdam, the Netherlands (Drs van Geel and Eggermont).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Differential Diagnosis, Investigation, and Current Treatment of Lower Limb Lymphedema
Tiwari et al.
Arch Surg 2003;138:152-161.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.